Today's Veterinary Business

DEC 2018

Today’s Veterinary Business provides information and resources designed to help veterinarians and office management improve the financial performance of their practices, allowing them to increase the level of patient care and client service.

Issue link: https://todaysveterinarybusiness.epubxp.com/i/1054694

Contents of this Issue

Navigation

Page 12 of 69

xx. The safe use with other anti-hypertensive medications has not been evaluated. Semintra® (telmisartan oral solution) is the fi rst FDA-approved angiotensin receptor blocker for fi rst-line treatment of cats with hypertension 1 Easy-to-use syringe allows for accurate dosing and fl exible dosing 2 Safe for long-term administration, with once-daily dosing after 14 days 1 I N T RODUC I NG The fi rst solution for hypertension NEW INDICATION IMPORTANT SAFETY INFORMATION SEMINTRA is an angiotensin II antagonist/angiotensin receptor blocker (ARB). Pregnant women should avoid contact with SEMINTRA because it can cause fetal and neonatal morbidity and death during pregnancy in humans. Pregnant women should avoid contact with SEMINTRA because other similar drugs have been found to harm the unborn baby during pregnancy. Precautions: SEMINTRA can cause mild anemia or non-regenerative anemia. Cats should be monitored for anemia when initiating treatment. Cats should be monitored for weight loss when initiating treatment with SEMINTRA. Use with caution in cats with a history of vomiting, inappetence, or weight loss. The safe use of SEMINTRA in cats with hepatic disease has not been evaluated. SEMINTRA is metabolized by the liver. SEMINTRA has not been evaluated in cats with systolic blood pressure > 200 mmHg. The safe use of SEMINTRA has not been evaluated in cats less than 9 months of age, or in cats that are pregnant, lactating, or intended for breeding. The safe use with other anti-hypertensive medications has not been evaluated. For additional information, see the full prescribing information on page (telmisartan oral solution) The safe use with other anti-hypertensive medications has not been evaluated. (telmisartan oral solution) References: 1. Semintra ® (telmisartan oral solution) Prescribing Information. Boehringer Ingelheim Vetmedica, Inc. 2018. 2. Zimmering T. Ease of use of Semintra® and its effects on quality of life—update on cat owner feedback ("EASY Programme") [abstract]. In: Proceedings from the 21st Federation of European Companion Animal Veterinary Associations (FECAVA); October 15 –17, 2015; Barcelona, Spain. Poster. Semintra ® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, licensed to Boehringer Ingelheim Vetmedica, Inc. © 2018 Boehringer Ingelheim Vetmedica, Inc. PET-0787-SEMI0918 18201 The safe use with other anti-hypertensive medications has not been evaluated. 12.

Articles in this issue

Archives of this issue

view archives of Today's Veterinary Business - DEC 2018